Gnak (Magnesium Chloride Hexahydrate, Potassium Chloride, Sodium Chloride, Glucose, Sodium Acetate Trihydr)

Gnak may be employed in clinical settings where intravenous electrolyte replacement or fluid therapy is required, particularly when patients need combined magnesium, potassium, and sodium supplementation together with an energy source.

• Restoration of magnesium levels in patients with hypomagnesemia during surgery or intensive care.
• Supplementation of potassium in individuals with hypokalemia or at risk of cardiac arrhythmias.
• Provision of sodium chloride to maintain extracellular fluid balance in dehydration.
• Delivery of glucose as an immediate carbohydrate source for energy metabolism.
• Support of acid‑base balance through sodium acetate conversion to bicarbonate.

The intravenous administration of Gnak can be associated with a range of observed effects, which are generally categorized by frequency and clinical significance.

Common

• Mild taste alteration or a metallic sensation experienced at the infusion site, typically resolving without intervention.
• Transient flushing or a sensation of warmth occurring during rapid infusion, which usually subsides shortly after the infusion is completed.
• Slight increase in urine output due to osmotic diuresis caused by the glucose component of the solution.
• Temporary elevation of serum electrolyte concentrations that normalizes after appropriate clinical monitoring and adjustment.

Serious

• Hypermagnesemia that may lead to hypotension, respiratory depression, or alterations in cardiac conduction, requiring prompt assessment and possible treatment.
• Severe hyperkalemia which can precipitate cardiac arrhythmias, muscle weakness, or paralysis, and may necessitate emergency medical intervention.

When using Gnak intravenously, healthcare professionals should observe several precautionary measures to minimize risks and ensure patient safety.

• Verify patient electrolyte levels and renal function before initiating infusion to avoid overload.
• Adjust infusion rate according to individual tolerance, especially in patients with cardiac or respiratory compromise.
• Monitor vital signs, including blood pressure and heart rhythm, throughout the administration.
• Perform regular serum magnesium, potassium, and sodium measurements during and after the infusion.
• Use caution in patients with neuromuscular disorders, as elevated magnesium may exacerbate weakness.
• Ensure compatibility with other intravenous solutions to prevent precipitation or incompatibility reactions.

Gnak may interact with other medications or solutions administered intravenously; awareness of potential interactions helps prevent adverse events.

Avoid

• Co‑administration with other magnesium‑containing products, which can cause excessive serum magnesium levels.
• Simultaneous infusion of calcium‑containing solutions, as magnesium and calcium may compete and significantly affect cardiac conduction.

Use with caution

• Loop diuretics, which may alter potassium and magnesium balance and increase risk of electrolyte disturbances.
• ACE inhibitors or ARBs, which can affect potassium homeostasis and raise the chance of hyperkalemia.
• Blood transfusions, because citrate in stored blood can bind calcium and influence electrolyte equilibrium.